利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

130 条记录 (耗时 0.023 秒)

    COMPOSITIONS AND METHODS FOR VIRAL EMBOLIZATION
    1.
    发明申请
    COMPOSITIONS AND METHODS FOR VIRAL EMBOLIZATION 审中-公开
    组合物和方法进行病毒整合

    公开(公告)号：WO2017037523A1

    公开(公告)日：2017-03-09

    申请号：PCT/IB2016/000993

    申请日：2016-06-17

    申请人： SILLAJEN, INC.

    发明人： HWANG, Tae, Ho ,  LEE, Nam, Hee ,  CHO, Mong ,  JEON, Ungbae ,  BYUN, Doo, Jin

    IPC分类号： A61K39/12 ,  A61K39/245 ,  A61K39/165 ,  A61K35/768 ,  A61K9/16

    CPC分类号： A61K9/0024 ,  A61K35/763 ,  A61K35/768 ,  A61K38/193 ,  A61K47/42 ,  A61K48/00 ,  C12N7/00 ,  A61K2300/00

    摘要： The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.

    摘要翻译： 本公开涉及用于使用经导管动脉病毒栓塞方法的溶瘤病毒。 本公开还提供了与适于主动栓塞的生物相容性微粒或亲水性聚合物凝胶剂组合的这种溶瘤病毒的组合物。 本公开进一步提供使用这种溶瘤病毒和组合物的经导管动脉病毒栓塞的方法，其优选地以减少肿瘤的方式。

    SYNTHETIC HERPES SIMPLEX VIRUSES FOR TREATMENT OF CANCERS
    7.
    发明申请
    SYNTHETIC HERPES SIMPLEX VIRUSES FOR TREATMENT OF CANCERS 审中-公开
    合成用于治疗癌症的简单病毒

    公开(公告)号：WO2011119925A3

    公开(公告)日：2012-06-21

    申请号：PCT/US2011029939

    申请日：2011-03-25

    申请人： UNIV LOUISIANA STATE ,  KOUSOULAS KONSTANTIN G ,  WALKER JASON

    发明人： KOUSOULAS KONSTANTIN G ,  WALKER JASON

    IPC分类号： C12N15/869 ,  A61P35/00 ,  C12N7/01 ,  C12N15/38 ,  C12N15/53

    CPC分类号： C12N7/00 ,  A61K35/763 ,  A61K45/06 ,  C12N2710/16632 ,  C12N2710/16643 ,  C12N2710/16662 ,  A61K2300/00

    摘要： New recombinant oncolytic viral vectors have been constructed based on a known herpes simplex virus-1 with a single 34.5 gene and a synctial mutation (called OncSyn (OS) virus), which was designed to be more immunogenic than the parental OS virus largely due to deletion of the viral gene viral host shutoff (vhs) gene (the "OSV" virus). In another embodiment, the OSV virus was constructed to constitutively express 15-PGDH (the "OSVP" virus), the principal enzyme responsible for degradation of PGE2. OSVP was shown to decrease both breast tumors and prostate cancer tumors in mice models. In addition, OSVP was shown to trigger substantial inflammatory cytokine production and promote anti-tumor immune responsiveness. These altered viruses, OSV and OSVP, can be used to treat various cancers including breast, prostate, liver, colon, and other tissues. Other exogenous genes can be added to either OSV or OSVP to improve the therapeutic response.

    摘要翻译： 已经基于已知的具有单个34.5基因和合成突变（称为OncSyn（OS）病毒）的单纯疱疹病毒-1构建了新的重组溶瘤病毒载体，其被设计为比亲本OS病毒更具免疫原性，主要是由于 病毒基因病毒宿主关闭（vhs）基因（“OSV”病毒）的缺失。 在另一个实施方案中，构建OSV病毒以组成型表达导致PGE2降解的主要酶的15-PGDH（“OSVP”病毒）。 OSVP显示在小鼠模型中减少乳腺肿瘤和前列腺癌肿瘤。 此外，OSVP被证明可以引发大量的炎性细胞因子产生并促进抗肿瘤免疫反应。 这些改变的病毒，OSV和OSVP可用于治疗各种癌症，包括乳腺癌，前列腺癌，肝癌，结肠癌和其他组织。 可以将其他外源基因加入到OSV或OSVP中以改善治疗反应。

    ONCOLYTIC VIRUS AS AN INDUCER FOR INNATE ANTITUMOR IMMUNITY
    8.
    发明申请
    ONCOLYTIC VIRUS AS AN INDUCER FOR INNATE ANTITUMOR IMMUNITY 审中-公开
    ONCOLYTIC VIRUS作为免疫抗体免疫的诱导剂

    公开(公告)号：WO2012071276A1

    公开(公告)日：2012-05-31

    申请号：PCT/US2011/061434

    申请日：2011-11-18

    申请人： ZHANG, Xiaoliu ,  FU, Xinping

    发明人： ZHANG, Xiaoliu ,  FU, Xinping

    IPC分类号： C12N7/01 ,  A61K35/76 ,  A61P35/00 ,  C12N15/63

    CPC分类号： A61K35/763 ,  A61K39/00 ,  C12N2710/16632 ,  G01N33/57484 ,  G01N2800/52

    摘要： The present invention is directed to the administration of FusOn-H2, an HSV derived oncolytic virus, to treat tumor cells that are resistant to the lytic effect of the virus. Administration of FusOn-H2 induces the patient's innate immune responses to tumor cells via neutrophils, which are able to destroy tumors efficiently when they migrate to the tumor mass. With the induced innate antitumor immunity, FusOn-H2 is effective at eradicating tumors even when it is used at very low doses.

    摘要翻译： 本发明涉及施用HSV衍生的溶瘤病毒的FusOn-H2来治疗对病毒的溶解作用有抗性的肿瘤细胞。 FusOn-H2的施用通过嗜中性粒细胞诱导患者对肿瘤细胞的先天免疫应答，当它们迁移到肿瘤块时能够有效地破坏肿瘤。 随着诱导的天然抗肿瘤免疫力，即使以非常低的剂量使用，FusOn-H2也有效消除肿瘤。

    A METHOD FOR INCREASING THE REPLICATION OF ONCOLYTIC HSVS IN HIGHLY RESISTANT TUMOR CELLS USING MTOR PATHWAY AND PI3K INHIBITORS
    9.
    发明申请
    A METHOD FOR INCREASING THE REPLICATION OF ONCOLYTIC HSVS IN HIGHLY RESISTANT TUMOR CELLS USING MTOR PATHWAY AND PI3K INHIBITORS 审中-公开
    使用MTOR途径和PI3K抑制剂增加高抗性肿瘤细胞中溶瘤HSVS复制的方法

    公开(公告)号：WO2012056327A2

    公开(公告)日：2012-05-03

    申请号：PCT/IB2011/003133

    申请日：2011-12-22

    申请人： ZHANG, Xiaoliu ,  FU, Xinping

    发明人： ZHANG, Xiaoliu ,  FU, Xinping

    IPC分类号： A61K35/76 ,  C12N7/00 ,  C12N5/09 ,  A61P35/00

    CPC分类号： A61K35/763 ,  A61K31/436 ,  A61K45/06 ,  C12N2710/16732 ,  A61K2300/00

    摘要： The present invention is directed to the administration of an HSV derived oncolytic virus and a PBK/AKT/mTOR pathway inhibitor to treat various types of resistant tumors. Therapy-resistant tumor formation is one of the main causes for treatment failure in the clinic. The treatment methods and compositions disclosed herein sensitize resistant tumors to the treatment of herpes simplex virus (HSV)-based oncolytic virotherapy. Pre or co-treatment of resistant tumor cells with the mTOR inhibitor, rapamycin, or certain PI3K inhibitors, such as LY294002, can efficiently sensitize the tumors to HSV derived oncolytic viruses, whereby the replication and spread of the viruses are dramatically enhanced.

    摘要翻译： 本发明涉及施用HSV衍生的溶瘤病毒和PI3K / AKT / mTOR通路抑制剂以治疗各种类型的耐药性肿瘤。 治疗耐药肿瘤形成是临床治疗失败的主要原因之一。 本文公开的治疗方法和组合物使抗性肿瘤对基于单纯疱疹病毒（HSV）的溶瘤病毒疗法的治疗敏感。 用mTOR抑制剂，雷帕霉素或某些PI3K抑制剂（例如LY294002）预先或共同治疗耐药肿瘤细胞可以有效地使肿瘤对HSV衍生的溶瘤病毒致敏，由此病毒的复制和传播显着增强。 p>